Tanner Hildegard, Hindricks Gerhard, Kottkamp Hans
Kardiologie - Abteilung für Rhythmologie/Elektrophysiologie, Universitat Leipzig-Herzzentrum.
Herz. 2005 Nov;30(7):613-8. doi: 10.1007/s00059-005-2749-7.
Antiarrhythmic drugs are used in at least 50% of patients who received an implantable cardioverter defibrillator (ICD). The potential indications for antiarrhythmic drug treatments in patients with an ICD are generally the following: reduction of the number of ventricular tachycardias (VTs) or episodes of ventricular fibrillation and therefore reduction of the number of ICD therapies, most importantly, the number of disabling ICD shocks. Accordingly, the quality of life should be improved and the battery life of the ICD extended. Moreover, antiarrhythmic drugs have the potential to increase the tachycardia cycle length to allow termination of VTs by antitachycardia pacing and reduction of the number of syncopes. In addition, supraventricular arrhythmias can be prevented or their rate controlled. Recently published or reported trials have shown the efficacy of amiodarone, sotalol and azimilide to significantly reduce the number of appropriate and inappropriate ICD shocks in patients with structural heart disease. However, the use of antiarrhythmic drugs may also have adverse effects: an increase in the defibrillation threshold, an excessive increase in the VT cycle length leading to detection failure. In this situation and when antiarrhythmic drugs are ineffective or have to be stopped because of serious side effects, catheter ablation of both monomorphic stable and pleomorphic and/or unstable VTs using modern electroanatomic mapping systems should be considered. The choice of antiarrhythmic drug treatment and the need for catheter ablation in ICD patients with frequent VTs should be individually tailored to specific clinical and electrophysiological features including the frequency, the rate, and the clinical presentation of the ventricular arrhythmia. Although VT mapping and ablation is becoming increasingly practical and efficacious, ablation of VT is mostly done as an adjunctive therapy in patients with structural heart disease and ICD experiencing multiple shocks, because the recurrence and especially the occurrence of "new" VTs after primarily successful ablation with time and disease progression have precluded a widespread use of catheter ablation as primary treatment.
至少50%接受植入式心脏复律除颤器(ICD)的患者使用了抗心律失常药物。ICD患者抗心律失常药物治疗的潜在适应证通常如下:减少室性心动过速(VT)的发作次数或室颤发作次数,从而减少ICD治疗的次数,最重要的是减少致残性ICD电击的次数。因此,应改善生活质量并延长ICD的电池寿命。此外,抗心律失常药物有可能增加心动过速周期长度,以便通过抗心动过速起搏终止VT并减少晕厥次数。另外,可预防室上性心律失常或控制其心率。最近发表或报道的试验表明,胺碘酮、索他洛尔和阿齐利特可显著减少结构性心脏病患者适当和不适当的ICD电击次数。然而,使用抗心律失常药物也可能有不良反应:除颤阈值增加,VT周期长度过度增加导致检测失败。在这种情况下,以及当抗心律失常药物无效或因严重副作用而必须停药时,应考虑使用现代电解剖标测系统对单形性稳定VT以及多形性和/或不稳定VT进行导管消融。对于频繁发作VT的ICD患者,抗心律失常药物治疗的选择和导管消融的必要性应根据特定的临床和电生理特征进行个体化调整,包括室性心律失常的频率、速率和临床表现。尽管VT标测和消融越来越实用和有效,但VT消融大多作为结构性心脏病和经历多次电击的ICD患者的辅助治疗,因为在初次成功消融后,随着时间推移和疾病进展,VT的复发尤其是“新”VT的出现阻碍了导管消融作为主要治疗方法的广泛应用。